MLTX

Moonlake Immunotherapeutics Health Care Pharmaceutical Preparations Russell 3000

$11.78Close $9.55 – $22.1652-week range Nov 4, 2026Next report

Highlights

Cautions

Not in an uptrend 0 of 8 trend conditions
Lagging the market RS 16 · weaker than 84% of stocks over 12 months
Far from its high 47% below its 52-week high
Results soon Nov 4, 2026, in 3 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 10, 2026

Off 12-month high 47%

1wk 0.6% price change

1mo 0.7% price change

12-month return 20% market up 11% · its own up 12%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B — price / book

Earnings yield — EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 61% return on equity

Free cash margin — -$196.0M FCF

D/E 0.24 long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 6.4% $0.75 a day · 2×ATR $10.28

RS 16 / 99 vs the universe

Trend 0 / 8 trend template

Relative volume 0.6× vs 50-day average

Up/down volume 0.69 50 sessions

Implied move — no option chain · report Nov 4, 2026

Trend template · 0 of 8

Screen verdict

Did not qualify for any screen.

Warning signs

none flagged

No restatement or impairment
Equity positive
Interest covered
No material dilution
Profits tracking cash
Margins and revenue not shrinking

Last reported Aug 10, 2026

Results reaction Aug 10, 2026-9% vs market2 sessions after results

Financials

5 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$227.3M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$196.0M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology $260.4M net cash

Cash
Long-term debt

	FY2021Dec 31, 2021	FY2022Dec 31, 2022	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Operating income	-$4.6M	-$65.1M	-$54.1M	-$143.1M	-$244.8M
Net income	-$4.5M	-$50.0M	-$36.0M	-$118.9M	-$227.3M
Earnings per share	-$0.01	-$1.70	-$0.73	-$1.89	-$3.53
Free cash flow	-$611,071	-$55.9M	-$43.1M	-$117.1M	-$196.0M
Cash	$8.0M	$39.5M	$451.2M	$180.4M	$334.5M
Long-term debt	—	—	—	$0	$74.1M
Shareholders' equity	-$11.6M	$48.9M	$495.7M	$446.8M	$304.5M

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 10, 2026	Quarterly ↗	Jun 30, 2026	41d
May 11, 2026	Quarterly ↗	Mar 31, 2026	41d
Feb 25, 2026	Annual ↗	Dec 31, 2025	56d
Nov 5, 2025	Quarterly ↗	Sep 30, 2025	36d
Aug 5, 2025	Quarterly ↗	Jun 30, 2025	36d
May 12, 2025	Quarterly ↗	Mar 31, 2025	42d
Feb 26, 2025	Annual ↗	Dec 31, 2024	57d
Nov 7, 2024	Quarterly ↗	Sep 30, 2024	38d
Aug 7, 2024	Quarterly ↗	Jun 30, 2024	38d
May 7, 2024	Quarterly ↗	Mar 31, 2024	37d
Feb 29, 2024	Annual ↗	Dec 31, 2023	60d
Nov 14, 2023	Quarterly ↗	Sep 30, 2023	45d

Current reports

Filed	Disclosed
Sep 30, 2026	Other events ↗
Aug 10, 2026	Results · Regulation FD ↗
Jul 15, 2026	Other events ↗
Jun 25, 2026	Material agreement ↗
Jun 22, 2026	Regulation FD · Other events ↗
Jun 9, 2026	Director or officer change · Shareholder vote ↗
Jun 1, 2026	Material agreement ↗
May 11, 2026	Results · Regulation FD ↗
Feb 23, 2026	Material agreement · Results · New obligation · Director or officer change · Regulation FD · Other events ↗
Jan 8, 2026	Other events ↗
Nov 5, 2025	Results · Regulation FD ↗
Nov 5, 2025	Material agreement ↗